You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Dow
Moodys
McKinsey
AstraZeneca
Baxter
McKesson

Last Updated: April 10, 2020

DrugPatentWatch Database Preview

Cilostazol - Generic Drug Details

» See Plans and Pricing

« Back to Dashboard

What are the generic sources for cilostazol and what is the scope of freedom to operate?

Cilostazol is the generic ingredient in two branded drugs marketed by Actavis Elizabeth, Apotex Inc, Breckenridge Pharm, Casi Pharms Inc, Chartwell Rx, Epic Pharma Llc, Hikma, Ivax Sub Teva Pharms, Mylan, Mylan Pharms Inc, Pliva Hrvatska Doo, Slate, Teva, and Otsuka, and is included in seventeen NDAs. Additional information is available in the individual branded drug profile pages.

There are twelve drug master file entries for cilostazol. Ten suppliers are listed for this compound.

Drug Prices for cilostazol

See drug prices for cilostazol

Drug Sales Revenue Trends for cilostazol

See drug sales revenues for cilostazol

Recent Clinical Trials for cilostazol

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Rennes University HospitalPhase 3
Ascension South East MichiganPhase 4
Wellcome TrustPhase 2

See all cilostazol clinical trials

Pharmacology for cilostazol
Synonyms for cilostazol
2(1H)-Quinolinone, 3,4-dihydro-6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-
2(1H)-Quinolinone, 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-
2(1H)-Quionlinone, 6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-
3,4-Dihydro-6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-2(1H)-quinolinone
6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-2(1H)-quinolinone
6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydrocarbostyril
6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydroquinolin-2(1H)-one
6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxyl)-3,4-dihydrocarobostyril
6-[4-(1-cyclohexyl-1,2,3,4-tetrazol-5-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one
6-[4-(1-cyclohexyl-1,2,3,4-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril
6-[4-(1-cyclohexyl-1H-1,2,3,4-tetrazol-5-yl)butoxy]-1,2,3,4-tetrahydroquinolin-2-one
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-1H-quinolin-2-one
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-2(1H)-quinolinone
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone
6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydroquinolin-2(1H)-one
6-[4-(1-cyclohexyl-5-tetrazolyl)butoxy]-3,4-dihydro-1H-quinolin-2-one
6-[4-(1-cyclohexyltetrazol-5-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one
6-[4-(l-cyclohexyl-1,2,3,4-tetrazol-5-yl)butoxyl]-3,4-dihydrocarbostyril
73963-72-1
89332-50-3
963C721
A837982
AB0012441
AB00382988_15
AB00382988_16
AB00382988-14
AB2000035
AC-4334
ACT02663
AK111532
AKOS015855512
AM90304
API0002016
BCP03724
BCP0726000145
BCP9000530
BCPP000279
BDBM50225508
BI7396
BRD-K67017579-001-04-2
BRD-K67017579-001-05-9
BRD-K67017579-001-07-5
BRD-K67017579-001-13-3
BRD-K67017579-001-17-4
BRN 3632107
BS0279
BSPBio_002759
C 0737
C-21103
C20H27N5O2
CAS-73963-72-1
CC-25783
CCG-39646
CHEBI:31401
CHEMBL799
Cilastatin sodium, Antibiotic for Culture Media Use Only
CILASTAZOL
Cilostazol (JP17/USAN/INN)
Cilostazol [INN:JAN]
Cilostazol [USAN:USP:INN:BAN:JAN]
Cilostazol, >=98% (HPLC), powder
Cilostazol, Pharmaceutical Secondary Standard; Certified Reference Material
Cilostazol, United States Pharmacopeia (USP) Reference Standard
Cilostazol,(S)
Cilostazole
Cilostazolum
Cilostazolum [INN-Latin]
CPD000058428
CS-1759
CTK8F0315
D01896
DB01166
DSSTox_CID_25132
DSSTox_GSID_45132
DSSTox_RID_80693
DTXSID9045132
EU-0100218
FT-0602474
FT-0645036
GTPL7148
HMS1922N15
HMS2093M14
HMS2096F16
HMS2234C06
HMS3260L17
HMS3268O09
HMS3412B18
HMS3654J13
HMS3676B18
HMS3713F16
HSDB 8312
HY-17464
J90029
KBio3_002259
KBioGR_001184
KM1582
KS-5154
Lopac-C-0737
Lopac0_000218
LP00218
LS-142693
MCULE-8893820969
MFCD00866780
MLS000028470
MLS000758281
MLS000759507
MLS001076067
MLS002153891
N7Z035406B
NCGC00015207-01
NCGC00015207-02
NCGC00015207-03
NCGC00015207-04
NCGC00015207-05
NCGC00015207-06
NCGC00015207-07
NCGC00015207-08
NCGC00015207-09
NCGC00015207-10
NCGC00015207-11
NCGC00015207-12
NCGC00022153-02
NCGC00022153-04
NCGC00022153-05
NCGC00022153-06
NCGC00022153-07
NCGC00260903-01
NSC-758936
NSC758936
OPC 13013
OPC 13013; OPC 21; Pletaal
OPC 21
OPC-13013
OPC-21
Opera_ID_488
OR13681
Pharmakon1600-01505230
Pletaal
Pletal
Pletal (TN)
Q-200854
Q258591
REGID_for_CID_2754
RETAL;PLETAL;OPC 21;PLETAAL;Cilostal
RRGUKTPIGVIEKM-UHFFFAOYSA-N
s1294
SAM001246734
SAM001247085
SBI-0050206.P002
SC-14107
SCHEMBL16128
SMR000058428
SPBio_001256
SPECTRUM1505230
Spectrum2_001118
Spectrum3_001170
Spectrum4_000772
Spectrum5_001762
SR-01000003107
SR-01000003107-10
SR-01000003107-2
SR-01000003107-4
SR-01000003107-7
ST24046323
SW199053-2
TC-063580
Tocris-1692
Tox21_110098
Tox21_110098_1
Tox21_500218
UNII-N7Z035406B
ZINC1552174
ZX-AFC000447
ZX-AT018851

US Patents and Regulatory Information for cilostazol

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Epic Pharma Llc CILOSTAZOL cilostazol TABLET;ORAL 077150-001 Mar 11, 2005 DISCN No No   Start Trial   Start Trial   Start Trial
Pliva Hrvatska Doo CILOSTAZOL cilostazol TABLET;ORAL 077898-002 Oct 29, 2007 DISCN No No   Start Trial   Start Trial   Start Trial
Mylan CILOSTAZOL cilostazol TABLET;ORAL 077323-001 Apr 20, 2006 DISCN No No   Start Trial   Start Trial   Start Trial
Epic Pharma Llc CILOSTAZOL cilostazol TABLET;ORAL 077022-001 Nov 23, 2004 DISCN No No   Start Trial   Start Trial   Start Trial
Actavis Elizabeth CILOSTAZOL cilostazol TABLET;ORAL 077028-002 Nov 26, 2004 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Moodys
McKinsey
AstraZeneca
Baxter
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.